SCHEMBL30714664

SCHEMBL30714664

Cn1nc2ccc(OCc3ccccn3)cc2c1C(=O)NC(C)(CO)CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 7/20 0.41
MAPK14 Q16539 6/20 0.41
PARP10 Q53GL7 1/20 0.39
CYP2C9 P11712 3/20 0.39
KCNH2 Q12809 1/20 0.39
CYP3A4 P08684 2/20 0.38
ALOX5 P09917 1/20 0.38
ALOX5AP P20292 1/20 0.38
GRM5 P41594 1/20 0.38
PPARG P37231 1/20 0.38
PDE5A O76074 2/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26869335 0.94 SMO (0.39) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL26869323 0.94 SMO (0.39) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL30714726 0.94 SMO (0.39) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL26868364 0.92 SMO (0.38) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL26868963 0.90 SMO (0.40) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL30714591 0.89 PARP10 (0.41) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL26869163 0.88 SMO (0.39) SMOMAPK14PARP10CYP2C9KCNH2
SCHEMBL30714665 0.87 NMT1 (0.43) MAPK14TSHR
SCHEMBL26868978 0.86 GUCY1B2 (0.43) SMOMAPK14CYP2C9KCNH2
SCHEMBL26696087 0.86 SMO (0.37) SMOMAPK14PARP10CYP2C9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 SMO 3806/4885MAPK14 2027/4885PARP10 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.